Discover 167 paid clinical trials in Fargo, North Dakota. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Filter
2
Filter results
Results: 167
Active & Responsive
VK2735 for Weight Management Phase 3
for
Weight Loss
Location: Fargo ND, Omaha NE, West Des Moines IA, Kansas City MO,
Sponsor: Viking Therapeutics, Inc.
Sex: All
Age: 18+
Code: NCT07104500
Phase3, Recruiting
New
Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)
Neoadjuvant Chemotherapy, Excision And Observation vs Chemoradiotherapy For Rectal Cancer
for
Rectal Cancer
Location: Fargo ND, Bemidji MN, Bismarck ND, Winnipeg,
Sponsor: Canadian Cancer Trials Group
Sex: All
Age: 18+
Code: NCT06205485
Phase3, Recruiting
Alcohol Related Impairment and Reinforcement: Pre to Post Roux en Y Gastric Bypass Surgery
for
Bariatric Surgery Candidate
Location: Fargo ND
Sponsor: Neuropsychiatric Research Institute, Fargo, North Dakota
Sex: All
Age: 21 - 65
Code: NCT02370732
Recruiting
TEMPUS ARIES: A Biobank Registry Platform Study in Oncology
for
Cancer
Location: Fargo ND, Rolling Meadows IL, Peoria IL, Hinsdale IL,
Sponsor: Tempus AI
Sex: All
Age: 18 - 70+
Code: NCT06207032
Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
for
Non Small Cell Lung Cancer
Location: Fargo ND, Minneapolis MN, Sioux Falls SD, St Louis MO,
Sponsor: Merck Sharp & Dohme LLC
Sex: All
Age: 18+
Code: NCT06312137
Phase3, Recruiting
KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)